Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial.

Vaccines (Basel) · 2025 · PMC12656800 · PMID 41295522

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The GMIs are highly significant, with the increasing number for the half-dose group being 3.25 dilution titer (95% CI 1.92–5.49) and the full-dose group being 5.04 dilution titer (2.00–12.68).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.